Clinical Trials Browser

INDUSTRY × Interventional × Hypersensitivity × Clear all

NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Phase 2 Active not recruiting

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

NCT04996875 2026-05-05

APEX

Phase 2 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

NCT06240741 2026-02-03

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

Phase 3 Completed

71 enrolled 37 charts

Hypersensitivity

NCT01033123 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Phase 2 Completed

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01033292 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Phase 2 Completed

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT00929162 2012-08-07

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

Phase 2 Terminated

120 enrolled 8 charts

Hypersensitivity, Neoplasms

NCT00116610 2009-01-21

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Phase 2 Completed

Hypersensitivity, Recurrence, Small Cell Lung Carcinoma